Steven Cohen Denali Therapeutics Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 333,530 shares of DNLI stock, worth $7.77 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
333,530
Previous 1,053,150
68.33%
Holding current value
$7.77 Million
Previous $24.5 Million
60.27%
% of portfolio
0.03%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding DNLI
# of Institutions
226Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Black Rock Inc. New York, NY13.2MShares$307 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$287 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$260 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$250 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$184 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.13B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...